Discussion
stroke, kidney disease
STROKE, KIDNEY DISEASE
The present study uses several national databases to obtain long-term clinical outcomes in a subset of ALLHAT participants. Posttrial follow-up of ALLHAT participants was accomplished by linking trial data with Medicare data from the CMS from 2002 to 2006.The use of administrative data has gained increased popularity in clinical trials and has been recognized by the US Food and Drug Administration as important to advance the development of therapeutic products.In contrast to the in-trial and 8-year to 13-year analyses, we now observed that the lisinopril group had an increased risk of kidney disease mortality that emerged after approximately 13 years after randomization, but this effect was attenuated after adjustment for baseline variables. During the in-trial period, lisinopril was associated with a higher risk of stroke, which persisted during our follow-up periods, as seen in the 